| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TISSUE-SPECIFIC STEM CELLS |
Department of Surgery, University of Regensburg, Regensburg, Germany
Key Words. Multipotent mesenchymal stromal cells • Liver regeneration • Hepatocyte transplantation • Dipeptidyl peptidase IV rat model • Transdifferentiation in vivo
Correspondence: Felix C. Popp, M.D., Department of Surgery, University of Regensburg, Franz-Josef-Strauss Allee 11, 93042 Regensburg, Germany, Telephone: 49-941-944-0; Fax: 49-941-944-6802; e-mail: felix.popp{at}klinik.uni-regensburg.de
Received August 16, 2006;
accepted for publication November 10, 2006.
First published online in STEM CELLS EXPRESS November 16, 2006.
Multipotent mesenchymal stromal (MS) cells from adult bone marrow are a cell population that can be expanded to large numbers in culture. MS cells might be differentiated toward hepatocytes in vitro and thus are promising candidates for therapeutic applications in vivo. The efficacy of bone marrow-derived MS cells versus hepatocytes to contribute to liver regeneration was compared in a rat model of prolonged toxic hepatic injury. Liver damage was induced by injection of carbon tetrachloride (CCl4) or allyl alcohol (AA) with and without retrorsine (R) pretreatment. MS cells or hepatocytes of wild-type F344 rats were injected into dipeptidyl peptidase IV (DPPIV)-deficient syngeneic rats. Hepatocyte chimerism was higher after intraportal hepatocyte transplantation in the R/AA group (mean maximal cluster size [MCS] = 21 cells) compared with the R/CCl4 treatment group (MCS = 18). No hepatocyte engraftment was outlined following post-transplant CCl4 injection only, whereas mere AA injection resulted in small clusters of donor-derived hepatocytes (MCS = 2). Intraparenchymal injection of hepatocytes was associated with a MCS = 11 after R/AA treatment and a MCS = 6 after AA administration alone. Redistribution of MS cells to the liver was shown after intraportal and intraparenchymal injection. In contrast to hepatocyte transplantation, however, donor-derived DPPIV-positive cells could not be demonstrated in any recipient after MS cell transplantation. Data from the present study indicate that a well-defined population of MS cells obtained according to established standard protocols does not differentiate into hepatocytes in vivo when transplanted under regenerative conditions, in which the application of hepatocytes results in stable hepatic engraftment.
This article has been cited by other articles:
|
|
 |
|
  A. Banas, T. Teratani, Y. Yamamoto, M. Tokuhara, F. Takeshita, M. Osaki, M. Kawamata, T. Kato, H. Okochi, and T. Ochiya IFATS Collection: In Vivo Therapeutic Potential of Human Adipose Tissue Mesenchymal Stem Cells After Transplantation into Mice with Liver Injury Stem Cells, October 1, 2008; 26(10): 2705 - 2712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Carvalho, L. F. Quintanilha, J. V. Dias, B. D. Paredes, E. G. Mannheimer, F. G. Carvalho, K. D. Asensi, B. Gutfilen, L. M. B. Fonseca, C. M. C. Resende, et al. Bone Marrow Multipotent Mesenchymal Stromal Cells Do Not Reduce Fibrosis or Improve Function in a Rat Model of Severe Chronic Liver Injury Stem Cells, May 1, 2008; 26(5): 1307 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Forbes Stem cell therapy for chronic liver disease choosing the right tools for the job Gut, February 1, 2008; 57(2): 153 - 155. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
